SCHEMBL864236

SCHEMBL864236

O=C(O)CC[C@H](O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 3/20 1.00
KDM4A O75164 2/20 1.00
KDM4C Q9H3R0 2/20 1.00
KDM2A Q9Y2K7 2/20 1.00
TET3 O43151 1/20 1.00
SMN1; SMN2 Q16637 1/20 0.52
FOLH1 Q04609 7/20 0.52
CYP1A2 P05177 2/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GSR P00390 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8032 1.00 TET2 (1.00) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL465914 1.00 TET2 (1.00) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL7509 1.00 TET2 (1.00) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL31620639 1.00 TET2 (1.00) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL29844290 1.00 TET2 (1.00) TET2KDM4AKDM4CKDM2ATET3
Water SCHEMBL23358414 0.97 TET2 (0.94) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL839512 0.97 TET2 (0.94) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL20598827 0.97 TET2 (0.94) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL19554357 0.97 TET2 (0.94) TET2KDM4AKDM4CKDM2ATET3
Lithium SCHEMBL31357194 0.97 TET2 (0.94) TET2KDM4AKDM4CKDM2ATET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12429423-B2 L-2-hydroxyglutarate biosensor based on specific transcriptional regulator and application thereof SHANDONG UNIVERSITY (CN) 2025-09-30 US claimed
EP-3453046-B1 GLUTARATE COMPOUNDS FOR TREATING ISCHEMIA-REPERFUSION INJURIES UNIV CALIFORNIA (US) 2025-07-09 EP claimed
US-20250000903-A1 EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES IOVANCE BIOTHERAPEUTICS, INC. 2025-01-02 US claimed
EP-4404969-A1 EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES Iovance Biotherapeutics, Inc. (US) 2024-07-31 EP claimed
CN-118243924-A Serum metabolic marker for diagnosing or monitoring bladder cancer and application thereof 宁夏医科大学总医院 2024-06-25 CN claimed
CN-118105416-A Application of Hericium coralloides in preparing medicine for treating depression induced by lipid metabolism abnormality 吉林农业大学 2024-05-31 CN claimed
US-11788112-B2 L-2-hydroxyglutarate and stress induced metabolism MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2023-10-17 US claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
WO-2023049862-A1 EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES IOVANCE BIOTHERAPEUTICS, INC. (US) 2023-03-30 WO claimed
CN-115856173-A Detection method of central carbon and amino acid and application thereof 北京诺禾致源科技股份有限公司 2023-03-28 CN claimed
WO-2017192413-A1 GLUTARATE COMPOUNDS FOR TREATING ISCHEMIA-REPERFUSION INJURIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-09 WO claimed
WO-2017189528-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME Ecolab USA, Inc. (US) 2017-11-02 WO claimed
CN-107299072-A Engineering bacterium and application thereof 江南大学 2017-10-27 CN claimed
CN-107109396-A Methods for fine-tuning gene expression using synthetically regulated sRNA 韩国科学技术院 2017-08-29 CN claimed
US-20170175164-A1 L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2017-06-22 US claimed
WO-2017076602-A1 METHODS OF T-LYMPHOCYTE EXPANSION CAMBRIDGE ENTERPRISE LIMITED (GB) 2017-05-11 WO claimed
EP-3122893-A1 L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM Memorial Sloan Kettering Cancer Center (US) 2017-02-01 EP claimed
WO-2015148950-A1 L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2015-10-01 WO claimed
EP-1326993-B1 PRODUCTION OF ALPHA-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM EXCELSYN MOLECULAR DEV LTD (GB) 2007-05-23 EP claimed
US-20040053382-A1 Production of alpha-hydroxy-carboxylic acids using a coupled enzyme system EXCELSYN MOLECULAR DEVELOPMENT LIMITED (GB) 2004-03-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000903-A1 EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES NFATC1, MKI67, ICOS TET2 6/4885KDM4A 105/4885KDM4C 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.